12/4/2024

Janusmed kön och genus

Janusmed kön och genus – ivermektin

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
A A
A A

Ivermektin - systemiskt

Ivermektin - systemiskt

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, Babalola OE et al. Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet. 1993;341(8838):130-4.

  2. Kebede A, Taticheff S, Bulto T, Workneh W, Tilahun D. Effect of ivermectin treatment on microfilarial load in patients with Onchocerca volvulus in Bebeka, Ethiopia. Ethiop Med J. 1993;31(2):127-35.

  3. Pion SD, Grout L, Kamgno J, Nana-Djeunga H, Boussinesq M. Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin. Acta Trop. 2011;120 Suppl 1:S91-9.

  4. Osungbade KO, Asuzu MC, Kale OO. Community-based treatment of onchocerciasis with ivermectin in southwest Nigeria: dermatological response to a singledose therapy. Afr J Med Med Sci. 2001;30(4):352-5.

  5. Subramanyam Reddy G, Vengatesvarlou N, Das PK, Vanamail P, Vijayan AP, Kala S et al. Tolerability and efficacy of single-dose diethyl carbamazine (DEC) or ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, south India. Trop Med Int Health. 2000;5(11):779-85.

  6. Pilger D, Heukelbach J, Khakban A, Oliveira FA, Fengler G, Feldmeier H. Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded controlled trial. Bull World Health Organ. 2010;88(2):90-6.

  7. Zubair SM, Chaudhry MW, Zubairi ABS, Shahzad T, Zahid A, Khan IA et al. The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness. Monaldi Arch Chest Dis. 2022;92(4).

  8. Zein AFMZ, Sulistiyana CS, Raffaelo WM, Pranata R. Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr. 2021;15(4):102186.

  9. Cartel JL, Moulia-Pelat JP, Glaziou P, Nguyen LN, Chanteau S, Roux JF. Results of a safety trial on single-dose treatments with 400 mcg/kg of ivermectin in bancroftian filariasis. Trop Med Parasitol. 1992;43(4):263-6.

  10. Bomze D, Sprecher E, Geller S. Severe cutaneous adverse reactions associated with systemic ivermectin: A pharmacovigilance analysis. J Dermatol. 2022;49(8):769-774.

  11. Chijioke CP. Factors affecting adverse event reporting during mass ivermectin treatment for onchocerciasis. Acta Trop. 2000;76(2):169-73.

  12. Clemmons L, Amazigo UV, Bissek AC, Noma M, Oyene U, Ekpo U et al. Gender issues in the community-directed treatment with ivermectin (CDTI) of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96 Suppl 1:S59-74.

  13. Gardon J, Macé JM, Cadot E, Ogil C, Godin C, Boussinesq M. Ivermectin-based control of onchocerciasis in northern Cameroon: individual factors influencing participation in community treatment. Trans R Soc Trop Med Hyg. 1996;90(3):218-22.

  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, Babalola OE et al. Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet. 1993;341(8838):130-4.
  2. Kebede A, Taticheff S, Bulto T, Workneh W, Tilahun D. Effect of ivermectin treatment on microfilarial load in patients with Onchocerca volvulus in Bebeka, Ethiopia. Ethiop Med J. 1993;31(2):127-35.
  3. Pion SD, Grout L, Kamgno J, Nana-Djeunga H, Boussinesq M. Individual host factors associated with Onchocerca volvulus microfilarial densities 15, 80 and 180 days after a first dose of ivermectin. Acta Trop. 2011;120 Suppl 1:S91-9.
  4. Osungbade KO, Asuzu MC, Kale OO. Community-based treatment of onchocerciasis with ivermectin in southwest Nigeria: dermatological response to a singledose therapy. Afr J Med Med Sci. 2001;30(4):352-5.
  5. Subramanyam Reddy G, Vengatesvarlou N, Das PK, Vanamail P, Vijayan AP, Kala S et al. Tolerability and efficacy of single-dose diethyl carbamazine (DEC) or ivermectin in the clearance of Wuchereria bancrofti microfilaraemia in Pondicherry, south India. Trop Med Int Health. 2000;5(11):779-85.
  6. Pilger D, Heukelbach J, Khakban A, Oliveira FA, Fengler G, Feldmeier H. Household-wide ivermectin treatment for head lice in an impoverished community: randomized observer-blinded controlled trial. Bull World Health Organ. 2010;88(2):90-6.
  7. Zubair SM, Chaudhry MW, Zubairi ABS, Shahzad T, Zahid A, Khan IA et al. The effect of ivermectin on non-severe and severe COVID-19 disease and gender-based difference of its effectiveness. Monaldi Arch Chest Dis. 2022;92(4).
  8. Zein AFMZ, Sulistiyana CS, Raffaelo WM, Pranata R. Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials. Diabetes Metab Syndr. 2021;15(4):102186.
  9. Cartel JL, Moulia-Pelat JP, Glaziou P, Nguyen LN, Chanteau S, Roux JF. Results of a safety trial on single-dose treatments with 400 mcg/kg of ivermectin in bancroftian filariasis. Trop Med Parasitol. 1992;43(4):263-6.
  10. Bomze D, Sprecher E, Geller S. Severe cutaneous adverse reactions associated with systemic ivermectin: A pharmacovigilance analysis. J Dermatol. 2022;49(8):769-774.
  11. Chijioke CP. Factors affecting adverse event reporting during mass ivermectin treatment for onchocerciasis. Acta Trop. 2000;76(2):169-73.
  12. Clemmons L, Amazigo UV, Bissek AC, Noma M, Oyene U, Ekpo U et al. Gender issues in the community-directed treatment with ivermectin (CDTI) of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96 Suppl 1:S59-74.
  13. Gardon J, Macé JM, Cadot E, Ogil C, Godin C, Boussinesq M. Ivermectin-based control of onchocerciasis in northern Cameroon: individual factors influencing participation in community treatment. Trans R Soc Trop Med Hyg. 1996;90(3):218-22.
  14. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]
A A
A A

Ivermektin - lokalt

Ivermektin - lokalt

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. Soolantra (ivermectin). Public Assessment Report - Scientific Disussion. European Medicines Agency (EMA) [updated 2014-09-04, cited 2023-01-09]

  2. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]

  1. Soolantra (ivermectin). Public Assessment Report - Scientific Disussion. European Medicines Agency (EMA) [updated 2014-09-04, cited 2023-01-09]
  2. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2022 [cited 2023-03-02.]